1. Home
  2. PLAB vs NRIX Comparison

PLAB vs NRIX Comparison

Compare PLAB & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLAB
  • NRIX
  • Stock Information
  • Founded
  • PLAB 1969
  • NRIX 2009
  • Country
  • PLAB United States
  • NRIX United States
  • Employees
  • PLAB N/A
  • NRIX N/A
  • Industry
  • PLAB Semiconductors
  • NRIX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PLAB Technology
  • NRIX Health Care
  • Exchange
  • PLAB Nasdaq
  • NRIX Nasdaq
  • Market Cap
  • PLAB 1.6B
  • NRIX 1.4B
  • IPO Year
  • PLAB 1987
  • NRIX 2020
  • Fundamental
  • Price
  • PLAB $24.38
  • NRIX $19.71
  • Analyst Decision
  • PLAB Strong Buy
  • NRIX Strong Buy
  • Analyst Count
  • PLAB 1
  • NRIX 17
  • Target Price
  • PLAB $35.00
  • NRIX $30.29
  • AVG Volume (30 Days)
  • PLAB 580.8K
  • NRIX 771.6K
  • Earning Date
  • PLAB 02-19-2025
  • NRIX 02-13-2025
  • Dividend Yield
  • PLAB N/A
  • NRIX N/A
  • EPS Growth
  • PLAB 2.96
  • NRIX N/A
  • EPS
  • PLAB 2.09
  • NRIX N/A
  • Revenue
  • PLAB $866,946,000.00
  • NRIX $56,424,000.00
  • Revenue This Year
  • PLAB $7.65
  • NRIX N/A
  • Revenue Next Year
  • PLAB $7.10
  • NRIX $3.79
  • P/E Ratio
  • PLAB $11.53
  • NRIX N/A
  • Revenue Growth
  • PLAB N/A
  • NRIX N/A
  • 52 Week Low
  • PLAB $20.25
  • NRIX $7.65
  • 52 Week High
  • PLAB $34.16
  • NRIX $29.56
  • Technical
  • Relative Strength Index (RSI)
  • PLAB 53.00
  • NRIX 49.01
  • Support Level
  • PLAB $24.07
  • NRIX $18.75
  • Resistance Level
  • PLAB $24.95
  • NRIX $20.15
  • Average True Range (ATR)
  • PLAB 0.66
  • NRIX 1.08
  • MACD
  • PLAB 0.08
  • NRIX 0.20
  • Stochastic Oscillator
  • PLAB 71.37
  • NRIX 75.00

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company that is principally engaged in manufacturing photomasks. The photomasks are photographic quartz plates that contain microscopic images of electronic circuits that are used as a component in the manufacture of integrated circuits and flat-panel displays. The revenue from products designed for integrated circuits production accounts for the majority of total revenue, with the rest derived from products for flat-panel display production. The company's assets are located in Taiwan, Korea, and the United States. It generates revenue worldwide, including in the United States, Europe, Taiwan, Korea, China, and elsewhere in Asia, with Taiwan contributing the majority of total revenue.

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Share on Social Networks: